Cornerstone Therapeutics (Nasdaq: CRTX) not only turned a slight profit this past quarter but also delivered potentially better news to investors on Thursday.
Craig Collard, chief executive officer of the company, said Cornerstone has received a response letter from the FDA about its proposed generic version of the cold treatment Tussionex. After responding to the FDA, Collard said he expects approval in “weeks, not months.”
WRAL Tech Wire content partner MedCity News has the details. Read here.
Get the latest news alerts: Follow WRAL Tech Wire at Twitter.